<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; pool</title>
	<atom:link href="http://www.tapanray.in/tag/pool/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Innovation: Is Big Pharma Talking Differently?</title>
		<link>http://www.tapanray.in/innovation-is-big-pharma-talking-differently/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovation-is-big-pharma-talking-differently</link>
		<comments>http://www.tapanray.in/innovation-is-big-pharma-talking-differently/#comments</comments>
		<pubDate>Mon, 17 Sep 2018 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[differently]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Egypt]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmasset]]></category>
		<category><![CDATA[pool]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[thinking]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9139</guid>
		<description><![CDATA[“Nearly 2 billion people have no access to basic medicines, causing a cascade of preventable misery and suffering. Good health is impossible without access to pharmaceutical products.” The World Health Organization’s (WHO) ‘Access to Medicine’ report on ‘Ten years in &#8230; <a href="http://www.tapanray.in/innovation-is-big-pharma-talking-differently/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovation-is-big-pharma-talking-differently/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Patent Pool’ – is GSK setting a new trend for the global pharmaceutical industry?</title>
		<link>http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/#comments</comments>
		<pubDate>Mon, 18 May 2009 00:30:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pool]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[setting]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[trend]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=884</guid>
		<description><![CDATA[On February 13, 2009, The Guardian reported that Andrew Witty, CEO of GlaxoSmithKline (GSK) announced some significant changes to the way his company will operate in the developing countries of the world. GSK, as Witty said, will: • “Cut its &#8230; <a href="http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Orphan Drugs’ for ‘Orphan Diseases’ – is ‘Open Source Drug Discovery (OSDD)’ platform for discovery research the way forward?</title>
		<link>http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward</link>
		<comments>http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/#comments</comments>
		<pubDate>Sun, 22 Feb 2009 09:30:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[forward]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[pool]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the way]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=962</guid>
		<description><![CDATA[To meet the unmet needs of common and dreaded diseases intensive R&#38;D activities are being undertaken by the Pharmaceutical Industry, the world over. At the same time, a percentage of human population, however small, also suffers from some rare diseases, &#8230; <a href="http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
